Publications

Protocol C publications, posted March 20019 (1-94)

  1. Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E. Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry.  2010;84(8):4100-4.^view
  2. Amornkul PN, Karita E, Kamali A, Rida WN, Sanders EJ, Lakhi S, et al. Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa2013;27(17):2775-86.^view
  3. Baalwa J, Wang S, Parrish NF, Decker JM, Keele BF, Learn GH, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013;436(1):33-48.^view
  4. Basu D, Xiao P, Ende Z, Bere A, Britt WJ, Mulenga J, et al. Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection. Virology. 2014;462-463:295-8.^view
  5. Bezemer D, Faria NR, Hassan A, Hamers RL, Mutua G, Anzala O, et al. HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya. AIDS Res Hum Retroviruses. 2014;30(2):118-26.^view
  6. Boeras DI, Hraber PT, Hurlston M, Evans-Strickfaden T, Bhattacharya T, Giorgi EE, et al. Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc Natl Acad Sci U S A. 2011;108(46):E1156-63.^view
  7. Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, et al. Impact of pre-adapted HIV transmission. Nat Med. 2016;22(6):606-13.^view
    Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science. 2014;345(6193):1254031.^view
  8. Cehovin A, Harrison OB, Lewis SB, Ward PN, Ngetsa C, Graham SM, Sanders EJ, Maiden MCJ, Tang CM.Identification of Novel Neisseria gonorrhoeae Lineages Harboring Resistance Plasmids in Coastal Kenya. J Infect Dis. 2018 Jul 24;218(5):801-808^view
  9. Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci U S A. 2015;112(12):E1480-9.^view
  10. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, et al. Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med. 2009;206(4):909-21.^view
  11. Crawford H, Matthews PC, Schaefer M, Carlson JM, Leslie A, Kilembe W, et al. The hypervariable HIV-1 capsid protein residues comprise HLA-driven CD8+ T-cell escape mutations and covarying HLA-independent polymorphisms. J Virol. 2011;85(3):1384-90.^view
  12. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2014;88(5):2489-507.^view
  13. Derdeyn CA, Moore PL, Morris L. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Current opinion in HIV and AIDS. 2014;9(3):210-6.^view
  14. Dilernia DA, Chien JT, Monaco DC, Brown MP, Ende Z, Deymier MJ, et al. Multiplexed highly-accurate DNA sequencing of closely-related HIV-1 variants using continuous long reads from single molecule, real-time sequencing. Nucleic Acids Res. 2015;43(20):e129.^view
  15. Du VY, Bansal A, Carlson J, Salazar-Gonzalez JF, Salazar MG, Ladell K, et al. HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection. J Immunol. 2016;196(8):3276-86.^view
  16. Erdmann N, Du VY, Carlson J, Schaefer M, Jureka A, Sterrett S, et al. HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses. PLoS Pathog. 2015;11(8):e1005111.^view
  17. Fast PE, Price MA, Rida WN, Kamali A, Karita E, International Aids Vaccine Initiative (IAVI) African Early Infection Research Group. WHO’s new guidelines for antiretroviral treatment. Lancet. 2013;382(9907):1778-9.^view
  18. Gilmour JW, Stevens WS, Gray C, de Souza M. Laboratory expansion to large-scale international HIV preventive vaccine trials. Current opinion in HIV and AIDS. 2007;2(3):201-6.^view
  19. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, Carlson JM, et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med. 2008;205(5):1009-17.^view
  20. Gounder K, Padayachi N, Mann JK, Radebe M, Mokgoro M, van der Stok M, et al. High frequency of transmitted HIV-1 Gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection. PLoS One. 2015;10(3):e0119886.^view
  21. Grebe E, Welte A, Hall J, Keating SM, Facente SN, Marson K, et al. Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms. J Acquir Immune Defic Syndr. 2017;76(5):547-55.^view
  22. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, Busch M, et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. The Lancet infectious diseases. 2009;9(12):747-59.^view
  23. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009;5(1):e1000274.^view
  24. Hassan AS, Mwaringa SM, Obonyo CA, Nabwera HM, Sanders EJ, Rinke de Wit TF, et al. Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya. AIDS Res Hum Retroviruses. 2013;29(1):129-35.^view
  25. Hassan AS,Esbjörnsson J, Wahome E, Thiong’o A, Makau GN, Price MA, Sanders EJ. HIV-1 subtype diversity, transmission networks and transmitted drug resistance amongst acute and early infected MSM populations from Coastal Kenya PLoS One. 2018 Dec 18;13(12): e0206177^view
  26. Havenar-Daughton C, Lindqvist M, Heit A, Wu JE, Reiss SM, Kendric K, et al. CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A. 2016;113(10):2702-7.^view
  27. Hu L, Song W, Brill I, Mulenga J, Allen S, Hunter E, et al. Genetic variations and heterosexual HIV-1 infection: analysis of clustered genes encoding CC-motif chemokine ligands. Genes Immun. 2012;13(2):202-5.^view
  28. Hue S, Hassan AS, Nabwera H, Sanders EJ, Pillay D, Berkley JA, et al. HIV type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination. AIDS Res Hum Retroviruses. 2012;28(2):220-4.^view
  29. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, et al. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol. 2009;83(16):8208-20.^view
  30. Kamali A, Price MA, Lakhi S, Karita E, Inambao M, Sanders EJ, et al. Creating an African HIV Clinical Research and Prevention Trials Network: HIV Prevalence, Incidence and Transmission. PLoS One. 2015;10(1):e0116100.^view
  31. Karita E, Price M, Hunter E, Chomba E, Allen S, Fei L, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS. 2007;21(4):403-8.^view
  32. Karita E, Price MA, Lakhi S, Kilembe W, Kamali A, Ruzagira E, et al. High Transmitter CD4+ T-Cell Count Shortly after the Time of Transmission in a Study of African Serodiscordant Couples. PLoS One. 2015;10(8):e0134438.^view
  33. Kassanjee R, McWalter TA, Welte A. Short Communication: Defining optimality of a test for recent infection for HIV incidence surveillance. AIDS Res Hum Retroviruses. 2014;30(1):45-9.^view
  34. Kassanjee R, Pilcher CD, Busch MP, Murphy G, Facente SN, Keating SM, et al. Viral load criteria and threshold optimization to improve HIV incidence assay characteristics – a CEPHIA analysis. AIDS. 2016.^view
  35. Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014;28(16):2439-49.^view
  36. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature. 2009;458(7238):641-5.^view
  37. Keating SM, Kassanjee R, Lebedeva M, Facente SN, MacArthur JC, Grebe E, et al. Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting “Recent” HIV Infection and Calculating Population Incidence. J Acquir Immune Defic Syndr. 2016;73(5):581-8.^view
  38. Khurana S, Needham J, Park S, Mathieson B, Busch MP, Nemo G, et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J Acquir Immune Defic Syndr. 2006;43(3):304-12.^view
  39. Khurana S, Norris PJ, Busch MP, Haynes BF, Park S, Sasono P, et al. HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. Journal of clinical microbiology. 2010;48(1):281-5.^view
  40. Kilembe W, Keeling M, Karita E, Lakhi S, Chetty P, Price MA, et al. Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. PLoS One. 2012;7(6):e37154.^view
  41. Kombo B, Sariola S, Gichuru E, Molyneux S, Sanders EJ, Elst Evd. “Facing Our Fears”: Using facilitated film viewings to engage communities in HIV research involving MSM in Kenya. Cogent Medicine. 2017;4
  42. Landais E, Huang X, Havenar-Daughton C, Murrell B, Price MA, Wickramasinghe L, et al. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. PLoS Pathog. 2016;12(1):e1005369.^view
  43. Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, et al. HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage. Immunity. 2017;47(5):990-1003 e9.^view
  44. Li X, Price MA, He D, Kamali A, Karita E, Lakhi S, et al. Host genetics and viral load in primary HIV-1 infection: clear evidence for gene by sex interactions. Human genetics. 2014;133(9):1187-97.^view
  45. Li X, Zhang K, Pajewski NM, Brill I, Prentice HA, Shrestha S, et al. Immunogenetic influences on acquisition of HIV-1 infection: consensus findings from two African cohorts point to an enhancer element in IL19 (1q32.2). Genes Immun. 2015;16(3):213-20.^view
  46. Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke MA, Arlehamn CL, et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013;39(4):758-69.^view
  47. Lynch RM, Rong R, Boliar S, Sethi A, Li B, Mulenga J, et al. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol. 2011;85(2):905-15.^view
  48. Lynch RM, Rong R, Li B, Shen T, Honnen W, Mulenga J, et al. Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Virology. 2010;404(1):59-70.^view
  49. MacLeod DT, Choi NM, Briney B, Garces F, Ver LS, Landais E, et al. Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity. 2016;44(5):1215-26.^view
  50. Malhotra R, Hu L, Song W, Brill I, Mulenga J, Allen S, et al. Association of chemokine receptor gene (CCR2-CCR5) haplotypes with acquisition and control of HIV-1 infection in Zambians. Retrovirology. 2011;8:22.^view
  51. Mastro TD, Kim AA, Hallett T, Rehle T, Welte A, Laeyendecker O, et al. Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward. Journal of HIV AIDS surveillance & epidemiology. 2010;2(1):1-14.^view
  52. Micheni M, Kombo BK, Secor A, Simoni JM, Operario D, van der Elst EM, et al. Health Provider Views on Improving Antiretroviral Therapy Adherence Among Men Who Have Sex with Men in Coastal Kenya. AIDS Patient Care STDS. 2017;31(3):113-21.^view
  53. Monaco DC, Dilernia DA, Fiore-Gartland A, Yu T, Prince JL, Dennis KK, et al. Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression. J Exp Med. 2016;213(10):2049-63.^view
  54. Muraguri N, Temmerman M, Geibel S. A decade of research involving men who have sex with men in sub-Saharan Africa: current knowledge and future directions. SAHARA J. 2012;9(3):137-47.^view
  55. Murphy G, Pilcher CD, Keating SM, Kassanjee R, Facente SN, Welte A, et al. Moving towards a reliable HIV incidence test – current status, resources available, future directions and challenges ahead. Epidemiol Infect. 2017;145(5):925-41.^view
  56. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog. 2013;9(2):e1003173.^view
  57. Musich T, O’Connell O, Gonzalez-Perez MP, Derdeyn CA, Peters PJ, Clapham PR. HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages. Retrovirology. 2015;12:25.^view
  58. Naarding MA, Fernandez N, Kappes JC, Hayes P, Ahmed T, Icyuz M, et al. Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. Journal of immunological methods. 2014;409:161-73.^view
  59. Nakibinge S, Maher D, Katende J, Kamali A, Grosskurth H, Seeley J. Community engagement in health research: two decades of experience from a research project on HIV in rural Uganda. Trop Med Int Health. 2009;14(2):190-5.^view
  60. Njai HF, Gombe B, Khamis T, Birungi J, Ruzagira E, Admassu D, et al. Setting Up a Standardized Peripheral Blood Mononuclear Cells Processing Laboratory to Support Multi-center HIV/AIDS Vaccine and Intervention Trials. Labmedicine. 2011;42(12):711-8.^://WOS:000297438300002
  61. Olson A, Bannert N, Sonnerborg A, de Mendoza C, Price M, Zangerle R, et al. Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. AIDS. 2018;32(2):161-9.^view
  62. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, et al. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. PLoS One. 2014;9(1):e86719.^view
  63. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, et al. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One. 2012;7(3):e32369.^view
  64. Peters PJ, Zulu I, Kancheya NG, Lakhi S, Chomba E, Vwalika C, et al. Modified Kigali combined staging predicts risk of mortality in HIV-infected adults in Lusaka, Zambia. AIDS Res Hum Retroviruses. 2008;24(7):919-24.^view
  65. Powers KA, Price MA, Karita E, Kamali A, Kilembe W, Allen S, et al. Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa. PLoS One. 2018;13(4):e0192785.^view
  66. Prentice HA, Lu H, Price MA, Kamali A, Karita E, Lakhi S, et al. Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection. J Virol. 2016;90(22):10423-30.^view
  67. Prentice HA, Pajewski NM, He D, Zhang K, Brown EE, Kilembe W, et al. Host genetics and immune control of HIV-1 infection: fine mapping for the extended human MHC region in an African cohort. Genes Immun. 2014;15(5):275-81.^view
  68. Prentice HA, Porter TR, Price MA, Cormier E, He D, Farmer PK, et al. HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race? J Virol. 2013;87(7):4043-51.^view
  69. Prentice HA, Price MA, Porter TR, Cormier E, Mugavero MJ, Kamali A, et al. Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates. Virology. 2014;449:254-62.^view
  70. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011;27(1):5-12.^view
  71. Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog. 2012;8(11):e1003041.^view
  72. Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, et al. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Med. 2015;12(4):e1001810.^view
  73. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 2009;5(9):e1000594.^view
  74. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206(6):1273-89.^view
  75. Sanchez AM, DeMarco CT, Hora B, Keinonen S, Chen Y, Brinkley C, et al. Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. Journal of immunological methods. 2014;409:117-30.^view
  76. Sanders EJ, Okuku HS, Smith AD, Mwangome M, Wahome E, Fegan G, et al. High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads following seroconversion among MSM. AIDS. 2013;27(3):437-46.^view
  77. Sanders EJ, Price MA, Karita E, Kamali A, Kilembe W, Bekker LG, et al. Differences in acute retroviral syndrome by HIV-1 subtype in a multicentre cohort study in Africa. AIDS. 2017;31(18):2541-6.^view
  78. van Santen D, van der Helm J, Touloumi G, Pantazis N, Muga R, Gunsenheimer-Bartmeyer B,  Gill M.J, Sanders E, Kelleher A; Zangerle R, Porter K, Prins M, Geskus R.Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. AIDS. 2019; 33(2): : 327–337. ^view
  79. Sethi A, Tian J, Derdeyn CA, Korber B, Gnanakaran S. A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. PLoS computational biology. 2013;9(5):e1003046.^view
  80. Smith SA, Burton SL, Kilembe W, Lakhi S, Karita E, Price M, et al. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth. PLoS Pathog. 2016;12(11):e1005989.^view
  81. Song W, He D, Brill I, Malhotra R, Mulenga J, Allen S, et al. Disparate associations of HLA class I markers with HIV-1 acquisition and control of viremia in an African population. PLoS One. 2011;6(8):e23469.^view
  82. Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, et al. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. HIV Med. 2018;19(3):184-94.^view
  83. Sullivan PS, Fideli U, Wall KM, Chomba E, Vwalika C, Kilembe W, et al. Prevalence of seroconversion symptoms and relationship to set-point viral load: findings from a subtype C epidemic, 1995-2009. AIDS. 2012;26(2):175-84.^view
  84. Tang J, Cormier E, Gilmour J, Price MA, Prentice HA, Song W, et al. Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes. J Virol. 2011;85(17):8894-902.^view
  85. Tang J, Li X, Price MA, Sanders EJ, Anzala O, Karita E, et al. CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data. Front Microbiol. 2015;6:670.^view
  86. Tang J, Malhotra R, Song W, Brill I, Hu L, Farmer PK, et al. Human leukocyte antigens and HIV type 1 viral load in early and chronic infection: predominance of evolving relationships. PLoS One. 2010;5(3):e9629.^view
  87. Tovanabutra S, Sanders EJ, Graham SM, Mwangome M, Peshu N, McClelland RS, et al. Evaluation of HIV type 1 strains in men having sex with men and in female sex workers in Mombasa, Kenya. AIDS Res Hum Retroviruses. 2010;26(2):123-31.^view
  88. van Santen DK, van der Helm JJ, Del Amo J, Meyer L, D’Arminio Monforte A, Price M, et al. Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014. J Hepatol. 2017;67(2):255-62.^view
  89. Wall KM, Kilembe W, Haddad L, Vwalika B, Lakhi S, Khu NH, et al. Hormonal Contraception, Pregnancy, Breastfeeding, and Risk of HIV Disease Progression Among Zambian Women. J Acquir Immune Defic Syndr. 2016;71(3):345-52.^view
  90. Wall KM, Rida W, Haddad LB, Kamali A, Karita E, Lakhi S, et al. Pregnancy and HIV Disease Progression in an Early Infection Cohort from Five African Countries. Epidemiology. 2017;28(2):224-32.^view
  91. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods. 2010;163(2):505-8.^view
  92. Westreich D, Pettifor A, Karita E, Price M, Fiamma A, Fiscus S, et al. Overestimation of the South African HIV incidence using the BED IgG assay? S Afr Med J. 2007;97(7):476, 8; author reply 8, 80.^view
  93. Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, et al. Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog. 2015;11(1):e1004565.^view
  94. Yue L, Prentice HA, Farmer P, Song W, He D, Lakhi S, et al. Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection. J Virol. 2013;87(2):708-15.^view
Menu